An anti-atherosclerosis drug greatly reduced blood-brain barrier (BBB) leaks in animal models with diabetes and hypercholesterolemia and linked BBB permeability with amyloid peptide deposits at the site of early Alzheimer’s pathology.
An anti-atherosclerosis drug greatly reduced blood-brain barrier (BBB) leaks in animal models with diabetes and hypercholesterolemia and linked BBB permeability with amyloid peptide deposits at the site of early Alzheimer’s pathology.